newsfilter
← Latest News
Business Wire·

Gamida Cell Reports Second Quarter and First Half 2023 Financial Results and Provides Company Update

Strong start for Omisirge® (omidubicel-onlv) launch with significant payer coverage and number of transplant centers onboarded exceeding expectations Company continues to pursue strategic partnership to further